What is the 13F Pro Quality Score for FIXX?

13F Pro ranks Q32 Bio Inc. (FIXX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FIXX's current score at https://13fpro.ai/company/FIXX (free sign-up required for the full ranking).

Where does 13F Pro source FIXX data?

All Q32 Bio Inc. fundamentals and ownership data come directly from SEC EDGAR. Q32 Bio Inc. files with the SEC under CIK 1661998. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FIXX in?

Q32 Bio Inc. (FIXX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FIXX research updated on 13F Pro?

FIXX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Q32 Bio Inc.(FIXX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661998 FIXX stock profile & AI dashboard →

13F Pro Quality Score

36.4/100

Rank #2,279 of 3,064 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

96.3/100

Earnings Quality

3.9/100

Free Cash Flow

30.0/100

Institutional Flow

92.5/100

Revenue Scale

30.0/100

Dilution Risk

15.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FIXX Scores 36/100

exact factor attribution · 2026-08-23

FIXX's composite is driven by capital efficiency and institutional flow, held back by earnings quality and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Capital efficiency

+4.6 pts

96th pct

Institutional flow

+2.1 pts

93th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.7 pts

16th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Earnings quality

-4.6 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

FIXX Stock Analysis & AI Quality Score

Data updated 2026-08-23

AI stock analysis and institutional research for Q32 Bio Inc. (FIXX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FIXX at 36.4/100 on a 32-signal composite quality model, placing it at rank #2,279 of 3,064 stocks — the bottom half of the AI-ranked universe. FIXX scores in the top quartile across balance sheet strength (96.3), institutional flow (92.5). Areas of concern include earnings quality (3.9) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.9/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of FIXX by reported 13-F value include ORBIMED ADVISORS, Boxer Capital Management, Atlas Venture Life Science Advisors, based on the most recent SEC filings. FIXX trades on the Nasdaq exchange and files with the SEC under CIK 1661998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FIXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Q32 Bio Inc. directly from SEC EDGAR. Q32 Bio Inc.'s 13F Pro composite quality score has ranged between 29 and 38 since 2026, currently 36.4 — an improving long-term trajectory across 31 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-8.9M

ROIC

Q2 2026

-34.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$53.7MFY 2025

FY22 $3.2MFY23 $-6.7MFY24 $0.00FY25 $53.7M

Net Income

+162.5% YoY

$29.8MFY 2025

FY22 $-5.0MFY23 $-53.7MFY24 $-47.7MFY25 $29.8M

Operating Income

+125.6% YoY

$16.9MFY 2025

FY22 $-133.3MFY23 $-48.3MFY24 $-66.1MFY25 $16.9M

EPS (Diluted)

+136.8% YoY

$2.42FY 2025

FY22 $-0.09FY23 $-153.96FY24 $-6.58FY25 $2.42

Total Assets

-33.1% YoY

$61.8MFY 2025

FY22 $228.5MFY23 $47.1MFY24 $92.3MFY25 $61.8M

Op. Cash Flow

+50.5% YoY

$-33.5MFY 2025

FY22 $-113.7MFY23 $-18.7MFY24 $-67.7MFY25 $-33.5M

Free Cash Flow

+50.5% YoY

$-33.5MFY 2025

FY22 $-114.9MFY23 $-18.7MFY24 $-67.8MFY25 $-33.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$53.7M	$0.00 +100.0%	$-6.7M -307.3%	$3.2M -90.6%	$34.0M +1157.3%	$2.7M
Net Income	$29.8M +162.5%	$-47.7M +11.2%	$-53.7M -973.8%	$-5.0M +94.8%	$-95.8M +25.6%	$-128.7M
Operating Income	$16.9M +125.6%	$-66.1M -37.0%	$-48.3M +63.8%	$-133.3M -38.9%	$-95.9M +26.3%	$-130.3M
EPS (Diluted)	$2.42 +136.8%	$-6.58 +95.7%	$-153.96 -170966.7%	$-0.09 +94.8%	$-1.73	—
Total Assets	$61.8M -33.1%	$92.3M +96.2%	$47.1M -79.4%	$228.5M +7.9%	$211.7M -19.7%	$263.7M
Operating Cash Flow	$-33.5M +50.5%	$-67.7M -262.6%	$-18.7M +83.6%	$-113.7M -3.6%	$-109.8M -16.3%	$-94.3M
Free Cash Flow	$-33.5M +50.5%	$-67.8M -262.9%	$-18.7M +83.7%	$-114.9M -2.5%	$-112.1M -14.4%	$-98.1M

Get alerted when FIXX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Q32 Bio Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FIXX

ORBIMED ADVISORS LLC
$52.6M4,127,987 sh
Boxer Capital Management, LLC
$40.1M3,149,310 sh
Atlas Venture Life Science Advisors, LLC
$34.6M2,717,106 sh
BVF INC/IL
$29.9M2,350,000 sh
RA CAPITAL MANAGEMENT, L.P.
$29.7M2,332,457 sh
Point72 Asset Management, L.P.
$14.9M1,173,396 sh
Opaleye Management Inc.
$11.9M931,000 sh
Logos Global Management LP
$10.2M800,000 sh
SummitTX Capital, L.P.
$9.3M733,774 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.6M518,803 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$52.6M	4,127,987
Boxer Capital Management, LLC	$40.1M	3,149,310
Atlas Venture Life Science Advisors, LLC	$34.6M	2,717,106
BVF INC/IL	$29.9M	2,350,000
RA CAPITAL MANAGEMENT, L.P.	$29.7M	2,332,457
Point72 Asset Management, L.P.	$14.9M	1,173,396
Opaleye Management Inc.	$11.9M	931,000
Logos Global Management LP	$10.2M	800,000
SummitTX Capital, L.P.	$9.3M	733,774
VANGUARD CAPITAL MANAGEMENT LLC	$6.6M	518,803

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FIXX on your watchlist

Track score changes the day Q32 Bio Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FIXX a good stock to buy?

13F Pro's AI-powered analysis of Q32 Bio Inc. (FIXX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FIXX are available on the FIXX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FIXX is classified as a small company.

Which hedge funds own FIXX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FIXX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Q32 Bio Inc.'s investment landscape.